bioAffinity Technologies, Inc., a Delaware corporation, has filed a Form 8-K with the Securities and Exchange Commission on March 26, 2026. This filing includes presentation materials that the company's management intends to use in discussions regarding the company's operations and performance. The presentation materials were made available on the company's website on the same date. The filing is categorized under Item 7.01, which pertains to Regulation FD Disclosure, and Item 9.01, which covers Financial Statements and Exhibits. The information provided in this filing is not considered 'filed' under the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. The filing also includes Exhibit 99.1, which contains the presentation materials for March 2026. This filing is part of the company's ongoing efforts to keep investors informed about its activities and performance metrics.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.